The firm will use to funds to validate its CD123-targeted CAR T-cell therapies in acute myeloid leukemia in clinical studies.

Through a new partnership, Caris will use its comprehensive genomic profiling tests to sequence more than 10,000 early-stage breast tumors collected in TAILORx.

Broad Institute and Northwestern University researchers are encouraging others to examine non-coding genes, when ...

About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

The firm will put the funds toward advancing its autologous CAR T-cell therapy MB-105 into Phase II clinical trials in CD5-positive lymphoma.